Loading

Richard Porter MA MSc FRCOG

  • Consultant Obstetrician and Gynaecologist, Royal United
  • Hospital, Bath

Kemadrin 5 mg without a prescription

These tumors have a poorer prognosis after commonplace chemotherapy medicine grapefruit interaction buy kemadrin 5 mg without a prescription, have a propensity to relapse early medications 2 times a day buy kemadrin master card, and have low responses charges to second-line therapy. Terms of Use � Privacy Policy � Notice � Accessibility T-cell/histiocyte-rich giant B-cell lymphoma is characterised by a lymphohistiocytic infiltrate with a diffuse or nodular growth sample. Interspersed within this background of T cells and histiocytes are particularly giant atypical B cells alone or in clusters that account for less than 10% of the overall infiltrate. Further info is supplied within the "Primary Extranodal Lymphomas" section of Chap. This is mostly seen in young and middle-aged adults with a female preponderance. The scientific presentation is usually with an anterior mediastinal mass with locoregional nodal involvement. Disseminated disease is comparatively uncommon at presentation; nevertheless, relapses after main remedy are inclined to be extranodal. Terms of Use � Privacy Policy � Notice � Accessibility subset inside the pivotal trial of axicabtagene ciloleucel. In the classical variant, signs vary from mild displays of fever of unknown origin to specific-organ options. B symptoms are current in roughly two-thirds of instances and are incessantly related to global functional decline. A proportion of sufferers might have cutaneous involvement with a range of dermatologic appearances. Finally, the hemophagocytic syndrome�associated variant of this illness presents with typical features of the hemophagocytic syndrome, which embody low blood counts, with hepatosplenomegaly and marrow involvement by the lymphoma. The inherited immunodeficiency syndromes related to lymphomas are mentioned in the "Immunosuppressed States" section of Chap. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. The t(14;18) is related to germinal center-derived diffuse large B-cell lymphoma and is a robust predictor of end result. Diffuse large B-cell lymphoma end result prediction b gene expression profiling and supervised machine studying. Distinct kinds of diffuse massive B-cell lymphoma identified by gene expression profiling. A probabilistic classification software for genetic subtypes of diffuse giant B cell lymphoma with therapeutic implications. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and a pair of. Favorable outcomes from allogeneic and autologous stem cell transplantation for sufferers with remodeled nonfollicular indolent lymphoma. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse massive B-cell non-Hodgkin lymphoma: a phase three comparability of dose intensification with 14-day versus 21-day cycles. Incidence and threat factors for central nervous system relapse in patients with diffuse giant B-cell lymphoma: analyses with competing threat regression mannequin. Rational administration schedule for high-dose methotrexate in sufferers with main central nervous system lymphoma. Lack of advantage of central nervous system prophylaxis for diffuse massive B-cell lymphoma within the rituximab era: findings from a large national database. The addition of rituximab reduces the incidence of secondary central nervous system involvement in sufferers with diffuse large B-cell lymphoma. Reactivation of hepatitis B virus infection in sufferers with hematologic issues. Role of prephase therapy prior to definitive chemotherapy in sufferers with diffuse massive B-cell lymphoma. Treatment of localized aggressive lymphomas with mixture chemotherapy followed by involved-field radiation remedy. Role of radiotherapy to cumbersome illness in aged patients with aggressive B-cell lymphoma. Outcomes of sufferers with double-hit lymphoma who achieve first complete remission. Targeting B-cell receptor signalling with ibrutinib in diffuse large B-cell Lymphoma. Fluorine-18-fluorodeoxyglucose positron emission tomography in response evaluation before high-dose chemotherapy for lymphoma: a scientific evaluation and meta-analysis. Polatuzumab vedotin together with immunochemotherapy in patients with beforehand untreated diffuse giant B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive lively remedy. A retrospective evaluation of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Non-myeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and remodeled indolent non-Hodgkin lymphoma. The activated B-cell subtype of diffuse massive B-cell lymphoma as determined by complete genome 30 / 34 116. Gene-expression profiling and never immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Molecular subtypes of diffuse giant B-cell lymphoma come up by distinct genetic pathways. Determining cell-of-origin subtypes of diffuse giant B-cell lymphoma utilizing gene expression in formalinfixed paraffin-embedded tissue. Confirmation of the molecular classification of diffuse massive B-cell lymphoma by immunohistochemistry using a tissue microarray. Immunohistochemical double-hit rating is a powerful predictor of end result in sufferers with diffuse giant B-cell lymphoma handled with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Impact of oncogene rearrangement patterns on outcomes in sufferers with double-hit nonHodgkin lymphoma. Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich massive B-cell lymphoma. T-cell-rich B-cell lymphoma: a clinicopathologic research of 21 cases and comparability with forty three cases of diffuse large B-cell lymphoma. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have related end result after chemotherapy: a matched-control evaluation. Outcomes of relapsed and refractory primary mediastinal (thymic) massive B cell lymphoma handled with second-line therapy and intent to transplant. Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma handled with Access Provided by: second-line remedy and intent to transplant.

5mg kemadrin

Factors affecting period of survival after onset of blastic transformation of chronic myeloid leukemia medicine 93 2264 purchase kemadrin 5 mg fast delivery. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast part in the tyrosine kinase inhibitor period: cohort study of 477 patients medications or drugs 5 mg kemadrin mastercard. Development and validation of a prognostic scoring system for sufferers with persistent myelomonocytic leukemia. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Autoimmune and inflammatory illnesses associated with persistent myelomonocytic leukemia: a sequence of 26 instances and literature evaluate. Leukapheresis in persistent myelomonocytic leukemia with leukostasis syndrome: elevated serum lactate ranges as an early sign of microcirculation failure. Clinical utility of classical and nonclassical monocyte proportion in the prognosis of persistent myelomonocytic leukemia. Chronic myelomonocytic leukemia requires granulocytic-macrophage colony-stimulating factor for progress in vitro and in vivo. Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. Chronic myelomonocytic leukemia: 2016 update on analysis, threat stratification, and administration. Natural historical past of chronic myelomonocytic leukemia handled with hypomethylating agents. Suboptimal response rates to hypomethylating agent remedy in chronic myelomonocytic leukemia; a single institutional study of 121 sufferers. Hypomethylating agent therapy use and survival in older sufferers with chronic myelomonocytic leukemia in the United States: a big population-based study. Azacitidine with or without lenalidomide in larger risk myelodysplastic syndrome & low blast acute myeloid leukemia. Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia. Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-free survival for sufferers with continual myelomonocytic leukemia. Integrating scientific features and genetic lesions in the danger assessment of patients with persistent myelomonocytic leukemia. Prognostic role of gene mutations in persistent myelomonocytic leukemia sufferers treated with hypomethylating agents. Increased cardiovascular comorbidities in sufferers with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations. Splenectomy in sufferers with persistent myelomonocytic leukemia: indications, histopathological findings and medical outcomes in a single institutional sequence of thirty-nine sufferers. The hypereosinophilic syndrome: evaluation of fourteen cases with a evaluation of the literature. World Health Organization-defined eosinophilic problems: 2019 update on analysis, �2021 McGraw Hill. Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome. Long-term clinical outcomes of high-dose mepolizumab therapy for hypereosinophilic syndrome. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with options just like persistent eosinophilic leukemia, not otherwise specified. Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Residual juvenile continual myelogenous leukemia cells detected in peripheral blood throughout scientific remission. The function of monocyte-derived hemopoietic growth elements in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia. Azacitidine is efficient for concentrating on leukemia-initiating cells in juvenile myelomonocytic juvenile persistent myelogenous leukemia. Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia. Transient hematologic and scientific effects of E21R in a baby with end-stage juvenile myelomonocytic leukemia. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood. B lineage acute lymphoblastic leukemia transformation in a child with juvenile myelomonocytic leukemia, sort 1 neurofibromatosis and monosomy of chromosome 7. Neoplastic involvement of granulocytic lineage, not granulocytic-monocytic, monocytic, or erythrocytic lineage, in a patient with continual neutrophilic leukemia. Recent progress in persistent neutrophilic leukemia and atypical persistent myeloid leukemia. Terms of Use � Privacy Policy � Notice � Accessibility handled with pegylated interferon alpha-2a. A case of continual neutrophilic leukemia successfully handled with pegylated interferon alpha-2a. Allogeneic bone marrow transplantation in the administration of chronic neutrophilic leukemia. Chronic neutrophilic leukemia associated with monoclonal gammopathy of undetermined significance. Lymphoid crisis with T-cell phenotypes in a affected person with Philadelphia chromosome adverse continual myeloid leukemia. Philadelphia-chromosome-negative persistent myelogenous leukemia with lymphoid stem cell blastic transformation. Characteristics and consequence of patients with Philadelphia chromosome negative, bcr/abl adverse chronic myelogenous leukemia. Haematological variations between persistent granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia. Page 123 / 124 Chapter 88: Chronic Myelogenous Leukemia and Related Disorders, Jane L. Targeted next era sequencing and identification of danger elements in World Health Organization defined atypical continual myeloid leukemia. Atypical persistent myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Allogeneic stem cell transplantation in sufferers with atypical persistent myeloid leukaemia: a retrospective examine from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

kemadrin 5 mg without a prescription

Cheap 5 mg kemadrin with amex

Mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of consequence during subsequent therapy medicine games buy kemadrin now. Characteristics and outcomes of sufferers with continual myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy treatment group order kemadrin online. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosomepositive leukemias with the T315I mutation. Dynamical models of mutated persistent myelogenous leukemia cells for a post-imatinib remedy situation: response to dasatinib or nilotinib remedy. Overexpression of the heat-shock protein 70 is related to imatinib resistance in chronic myeloid �2021 McGraw Hill. Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Beyond dose escalation: scientific choices for relapse or resistance in persistent myelogenous leukemia. Dasatinib or high-dose imatinib for chronic-phase continual myeloid leukemia after failure of firstline imatinib: a randomized section 2 trial. Dasatinib crosses the blood�brain barrier and is an efficient remedy for central nervous system Philadelphia chromosome-positive leukemia. Long-term end result with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: followup of a part three research. Quality of life and adherence to therapy in sufferers with continual myeloid leukemia handled with nilotinib as a second-line remedy: a multicenter prospective observational examine. Bosutinib is active in continual part continual myeloid leukemia after imatinib and dasatinib and/or nilotinib remedy failure. Factors influencing long-term efficacy and tolerability of bosutinib in chronic section persistent myeloid leukaemia resistant or illiberal to imatinib. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Ponatinib reduces viability, migration, and functionality of human endothelial cells. Comparative efficacy of tyrosine kinase inhibitor remedies in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia sufferers. Healthcare utilization and costs related to tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia. Outcomes of newly diagnosed continual part persistent myeloid leukemia following an elective switch from second-generation tyrosine kinase inhibitor to imatinib. Incidence and administration of myelosuppression in sufferers with chronic- and accelerated-phase persistent myeloid leukemia treated with omacetaxine mepesuccinate. Subcutaneous omacetaxine mepesuccinate in sufferers with chronic-phase chronic myeloid leukemia beforehand handled with 2 or extra tyrosine kinase inhibitors together with imatinib. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase persistent myeloid leukemia patients resistant to or illiberal of tyrosine kinase inhibitors. Bortezomib and flavopiridol work together synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate by way of each Bcr/Abl-dependent and -independent mechanisms. Hedgehog signaling is essential for upkeep of cancer stem cells in myeloid leukaemia. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Imatinib mesylate in combination with different hemotherapeutic medicine: in vitro research. Homoharringtonine and low-dose cytarabine within the administration of late chronic-phase chronic myelogenous leukemia. Recent advances in Philadelphia chromosome-positive malignancies: the potential position of arsenic trioxide. Results of decitabine (5-aza-2-deoxycytidine) remedy in one hundred thirty patients with chronic myelogenous leukemia. Phase 1 research of low-dose extended publicity schedules of the hypomethylating agent 5-aza-2deoxycytidine (decitabine) in hematopoietic malignancies. Combination of low-dose imatinib plus nilotinib for the therapy of chronicphase continual myeloid leukaemia after imatinib failure. Combination of low-dose imatinib plus nilotinib for the treatment of chronic- section chronic myeloid leukaemia after imatinib failure. Imatinib mesylate related to delayed hematopoietic restoration after concomitant chemotherapy. Failure to obtain a serious cytogenetic response by 12 months defines insufficient response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Survival benefit from imatinib compared with the combination interferon-alpha plus cytarabine in chronicphase persistent myelogenous leukemia: historic comparability between two part three trials. Interferon-alfa-based remedy of chronic myeloid leukemia and implications of signal transduction inhibition. Imatinib mesylate remedy in persistent myeloid leukemia patients in secure complete cytogenic response after interferon-alpha results in a really excessive full molecular response price. Efficacy and security of imatinib in patients with continual myeloid leukemia and full or near-complete cytogenetic response to interferon-alpha. Terms of Use � Privacy Policy � Notice � Accessibility of survival by hydroxyurea. Interferon alfa-2b combined with cytarabine versus interferon alone in continual myelogenous leukemia. Randomized comparison of busulfan and hydroxyurea in continual myelogenous leukemia: prolongation of survival by hydroxyurea. Targeting peroxisome proliferator-activated receptors: a novel technique for Philadelphia chromosome-positive leukemia cells. Terms of Use � Privacy Policy � Notice � Accessibility sufferers with continual myelogenous leukemia or 627. Splenic irradiation within the therapy of sufferers with continual myelogenous leukemia or myelofibrosis and myeloid metaplasia. Results of a potential randomized trial of early splenectomy in continual myeloid leukemia. Splenectomy in persistent myeloid leukemia and myelofibrosis with myeloid metaplasia. A retrospective evaluation of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for persistent myelogenous leukemia. Management of continual myeloid leukemia within the setting of being pregnant: when is leukocytapheresis applicable Successful childbirth in a affected person with continual myelogenous leukemia handled with imatinib mesylate during early pregnancy. Outcome of discontinuation of imatinib therapy after achieving a molecular remission.

5mg kemadrin

Buy kemadrin on line amex

Reactive middle defects carry the largest threat of thrombosis treatment 1st degree heart block order kemadrin 5 mg with visa, whereas heparin-binding defects are associated with much less danger of venous thrombosis (Chap symptoms pregnancy order 5 mg kemadrin overnight delivery. No protease has yet been identified as the goal of the K3 protease inhibitor domain. Curiously, the protease-like domain of protein Z lacks any protease exercise as a result of it has mutations at two of the three energetic website triad residues. No association between defects in bleeding or thrombosis has been confirmed for this inhibitor. An enzyme cascade in the blood clotting mechanism and its operate as a biochemical amplifier. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. Radioimmunoassay of fibrinopeptides in relation to intravascular coagulation and thrombosis. The pathophysiology of the prethrombotic state in people: insight gained from studies utilizing markers of hemostatic system activation. Mathematical evaluation of a proteolytic positive-feedback loop: dependence of lag time and enzyme yields on the initial circumstances and kinetic parameters. Mathematical evaluation of activation thresholds in enzyme-catalyzed constructive feedbacks: software to the feedbacks of blood coagulation. The interplay between the endothelial cell protein C receptor and protein C is dictated by the gamma-carboxyglutamic acid domain of protein C. Patterns revealed by three-dimensional molecular modelling of mutations of the protease domain. The autolysis loop of activated protein C interacts with issue Va and differentiates between the Arg506 and Arg306 cleavage sites. Secondary substrate-binding exosite within the serine protease area of activated protein C necessary for cleavage at Arg-506 however not at Arg-306 in factor Va. Characterization of a thrombomodulin binding website on protein C and its comparability to an activated protein C binding web site for issue Va. Molecular characterization of an extended binding site for coagulation issue Va in the optimistic exosite of activated protein C. Activated protein C variants with normal cytoprotective but decreased anticoagulant exercise. Activated protein C mutant with minimal anticoagulant exercise, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant however not its protective signaling properties. Identification of a particular exosite on activated protein C for interplay with protease activated receptor forty four. Identification of a specific exosite on activated protein C for interaction with protease activated receptor 1. Possible structural implications of 20 mutations in the protein C protease area. Identification and computationally-based structural interpretation of naturally occurring variants of human protein C. Dysfunction of protein C anticoagulant system, main genetic threat factor for venous thromboembolism in northeast Asians. Expression and practical characterisation of pure R147W and K150del variants of protein C in the Chinese population. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. Characterization of protein S, a gamma-carboxyglutamic acid containing protein from bovine and human plasma. Identification of residues 413-433 of plasma protein S as essential for binding to C4b-binding protein. Protein S-K196E mutation as a genetic danger issue for deep vein thrombosis in Japanese sufferers. Heerlen polymorphism of protein S, an immunologic polymorphism because of dimorphism of residue 460. Identification of an endothelial cell cofactor for thrombin catalyzed activation of protein C. Complex formation between thrombin and thrombomodulin inhibits each thrombin-catalyzed fibrin formation and issue V activation. A common thrombomodulin amino acid dimorphism is related to myocardial infarction. A mutation within the thrombomodulin gene, 127G to A coding for Ala25Thr, and the danger of myocardial infarction in males. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. Thrombin activatable fibrinolysis inhibitor, a possible regulator of vascular irritation. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. The endothelial cell protein C receptor augments protein C activation by the thrombinthrombomodulin complex. Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation. Activation mechanism of anticoagulant protein C in giant blood vessels involving the endothelial cell protein C receptor. Nucleotide construction and characterization of the murine gene encoding the endothelial cell protein C receptor. The crystal construction of the endothelial protein C receptor and a sure phospholipid. Structural prediction and analysis of endothelial cell protein C/activated protein C receptor. Protease-activated receptor signalling by coagulation proteases in endothelial cells. The protein C pathway in tissue irritation and harm: pathogenic position and therapeutic implications. The Ser219->Gly dimorphism of the endothelial protein C receptor contributes to the upper soluble protein levels noticed in individuals with the A3 haplotype. Plasma ranges of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of various pathological processes. Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. Severe malaria is related to parasite binding to endothelial protein C receptor. Loss of endothelial protein C receptors hyperlinks coagulation and irritation to parasite sequestration in cerebral malaria in African kids.

cheap 5 mg kemadrin with amex

Diseases

  • Cheilitis glandularis
  • Adrenal hypertension
  • Opthalmoplegia progressive external scoliosis
  • Bilateral renal agenesis dominant type
  • 3 hydroxyisobutyric aciduria
  • Coloboma chorioretinal cerebellar vermis aplasia
  • Gemss syndrome

buy kemadrin on line amex

Cheap 5mg kemadrin with mastercard

A section 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory a quantity of myeloma treatment ulcerative colitis discount kemadrin on line. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy medicine to calm nerves cheap 5 mg kemadrin fast delivery. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: outcomes of a Phase I clinical trial. Lenalidomide in combination with dexamethasone for the remedy of relapsed or refractory a number of myeloma. Donor leukocyte infusions are efficient in relapsed multiple myeloma after allogeneic bone marrow transplantation. Minimal residual disease after bone marrow transplantation for multiple myeloma: proof for cure in longterm survivors. Molecular and scientific remissions in a number of myeloma: function of autologous and allogeneic transplantation of hematopoietic cells. Outcome after autologous and allogeneic stem cell transplantation for sufferers with multiple myeloma: impression of graft-versus-myeloma impact. Allogeneic marrow transplantation for a number of myeloma: an evaluation of danger components on end result. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched examine from the European Group for Blood and Marrow Transplantation. Prognostic components in allogeneic bone marrow transplantation for a quantity of myeloma. Treatment of myeloma utilizing intensive remedy and allogeneic bone marrow transplantation. Analysis of consequence following allogeneic haemopoietic stem cell transplantation for myeloma utilizing myeloablative conditioning�evidence for a superior consequence using melphalan mixed with complete physique irradiation. Transplantation in patients with a quantity of myeloma: a multicenter comparative evaluation of peripheral blood stem cell and allogeneic transplant. Syngeneic transplantation in multiple myeloma-a case-matched comparison with autologous and allogeneic transplantation. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia with out myeloablative remedy. Nonmyeloablative stem cell transplantation and cell therapy as an various to typical bone marrow transplantation with lethal cytoreduction for the therapy of malignant and nonmalignant hematologic ailments. Immunotherapy by non-myeloablative allogeneic stem cell transplantation in a number of myeloma: results of a pilot research as salvage remedy after autologous transplantation. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation elements on outcome. Reduced depth conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy. Autologous stem cell transplantation adopted by a dose-reduced allograft induces high full remission price in multiple myeloma. Nonmyeloablative allografting for newly identified multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Nonmyeloablative allografting for newly identified multiple myeloma: the expertise of the Gruppo Italiano Countway Medical Library Trapianti di Midollo. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. Molecular monitoring of minimal residual illness in patients in long-term complete remission after allogeneic stem cell transplantation for a quantity of myeloma. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter research. T-cell�depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in sufferers with a number of myeloma: induction of graft-versus-myeloma effect. Pamidronate within the treatment of osteolytic bone lesions in multiple myeloma patients-the American expertise. Zoledronic acid is superior to pamidronate within the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled medical trials. International Myeloma Working Group recommendations for the remedy of a number of myelomarelated bone disease. Kyphoplasty within the therapy of osteolytic vertebral compression fractures as a result of multiple myeloma. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer sufferers. Prothrombotic coagulation abnormalities in patients with newly diagnosed a quantity of myeloma. Genetic associations with thalidomide mediated venous thrombotic events in myeloma recognized utilizing targeted genotyping. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in aged sufferers with a quantity of myeloma: randomised controlled trial. Effect on survival of treatment-associated venous thromboembolism in newly diagnosed a number of myeloma patients. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic threat factors: potential cohort research. Development of neuropathy in sufferers with myeloma handled with thalidomide: patterns of incidence and the 571. Incidence of recurrent venous thromboembolism in relation to medical and thrombophilic risk elements: Countway Medical Library prospective cohort research. Bortezomib-induced peripheral neuropathy in multiple myeloma: a complete review of the literature. Development of neuropathy in patients with myeloma handled with thalidomide: patterns of occurrence and the function of electrophysiologic monitoring. Neurotoxicity of bortezomib therapy in a quantity of myeloma: a single-center expertise and review of the literature. Neuropathy in a number of myeloma sufferers handled with bortezomib: a multicenter expertise. Frequency, characteristics, and reversibility of peripheral neuropathy throughout treatment of advanced a quantity of myeloma with bortezomib. Subcutaneous versus intravenous administration of bortezomib in sufferers with relapsed a quantity of myeloma: a randomised, section 3, non-inferiority research. Thalidomide for sufferers with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter part 2 research of efficacy, toxicity, and biological exercise.

Purchase kemadrin from india

Genetic markers of steady molecular remission in continual myeloid leukemia after focused remedy discontinuation kapous treatment kemadrin 5 mg online. Discontinuing tyrosine kinase inhibitor therapy in chronic myelogenous leukemia: present understanding and future directions medicine hat news generic 5mg kemadrin. When to stop tyrosine kinase inhibitors for the treatment of continual myeloid leukemia. Autologous stem cell transplantation in chronic myeloid leukaemia: a meta-analysis of six randomized trials. Drug therapy is superior to allografting as first-line remedy in chronic myeloid leukemia. Long-term end result of sufferers with newly diagnosed continual myeloid leukemia: a randomized comparability of stem cell transplantation with drug treatment. Allogeneic hematopoietic stem cell transplantation is an effective salvage remedy for sufferers with persistent myeloid leukemia presenting with superior disease or failing therapy with tyrosine kinase inhibitors. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or every day schedule to sufferers with superior hematologic malignant illness undergoing stem cell transplantation. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia sufferers present process hematopoietic cell transplant through the tyrosine kinase inhibitor period. Splenic irradiation earlier than hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. Three decades of allogeneic bone marrow transplants at the Princess Margaret Hospital. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Long-term outcomes after allogeneic bone marrow transplantation for persistent myelogenous leukemia in persistent phase: a report from the Chronic Leukemia Working Party of the European Groups for Blood and Marrow Transplantation. The effects of imatinib mesylate remedy earlier than allogeneic transplantation for persistent myeloid �2021 McGraw Hill. Long-term outcomes after allogeneic bone marrow transplantation for continual myelogenous leukemia in Countway Medical Library continual part: a report from the Chronic Leukemia Working Party of the European Groups for Blood and Marrow Transplantation. The effects of imatinib mesylate treatment earlier than allogeneic transplantation for persistent myeloid leukemia. Novel tyrosine kinase inhibitor therapy earlier than allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Clinical influence of pretransplant use of a number of tyrosine kinase inhibitors on the finish result of allogeneic hematopoietic stem cell transplantation for persistent myelogenous leukemia. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for sufferers with continual myeloid leukemia. Kinetics of minimal residual disease and chimerism in sufferers with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Reduced-intensity allogeneic hematopoietic stem cell transplantation mixed with imatinib has comparable event-free survival and total survival to long-term imatinib therapy in younger sufferers with chronic myeloid leukemia. Maintenance therapy with tyrosine kinase inhibitors after transplant in sufferers with persistent myeloid leukemia. Terms of Use � Privacy Policy � Notice � Accessibility predominantly relapse with the identical mutation. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive. Phase half examine of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with superior continual myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Immunological results of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with superior persistent myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Dasatinib use and danger of cytomegalovirus reactivation after allogeneic hematopoietic-cell transplantation. Does post-transplant upkeep remedy with tyrosine kinase inhibitors improve outcomes of patients with high-risk Philadelphia chromosome-positive leukemia Donor leukocyte transfusions for remedy of recurrent continual myelogenous leukemia in marrow transplant sufferers. Donor lymphocyte infusion for relapse of persistent myeloid leukemia after allogeneic stem cell transplant: where we now stand. Relapse of persistent myeloid leukemia after allogeneic bone marrow transplant: the case of giving donor leukocyte transfusions before the onset of hematologic relapse. Unrelated donor leukocyte infusions to deal with relapse after unrelated donor bone marrow transplantation. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Graft-versus-host illness and graft-versus-leukemia after donor leukocyte infusion. Terms of Use � Privacy Policy � Notice � Accessibility allogeneic bone marrow transplantation. Donor lymphocyte infusion for relapsed continual myelogenous leukemia: prognostic relevance of the initial cell dose. Life expectancy of patients with persistent myeloid leukemia approaches the life expectancy of the general population. The influence of introducing tyrosine kinase inhibitors on persistent myeloid leukemia survival: a population-based examine. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the period of tyrosine kinase inhibitor therapy. Success of targeted remedy in chronic myeloid leukemia: a population-based research of sufferers identified in Sweden from 1973 to 2008. Outcome of sufferers with Philadelphia chromosome-positive persistent myelogenous leukemia postimatinib mesylate failure. Disease-related mortality exceeds treatment-related mortality in patients with persistent myeloid leukemia on second-line or later remedy. Smokers with chronic myeloid leukemia are at a better danger of disease progression and untimely death. Long-term consequence of persistent myeloid leukemia patients handled frontline with imatinib. Long-term follow-up of de novo continual phase chronic myelogenous leukemia sufferers on frontline imatinib. Pattern of use and long-term safety of tyrosine kinase inhibitors: a decade of real-world management of continual myeloid leukemia. Incidence of second malignancies in sufferers with chronic myeloid leukemia within the era of tyrosine kinase inhibitors. Incidence and outcome of second malignancies in sufferers with persistent myeloid leukemia throughout treatment with tyrosine kinase inhibitors. Incidence of second major malignancies and related mortality in sufferers with imatinib-treated persistent myeloid leukemia. Terms of Use � Privacy Policy � Notice � Accessibility [PubMed: 29388066] Countway Medical Library 763. Incidence and end result of second malignancies in sufferers with continual myeloid leukemia throughout Access Provided by: treatment with tyrosine kinase inhibitors. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in sufferers with newly identified chronic-phase persistent myeloid leukemia.

Cheap kemadrin 5mg

Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and seem to be derived from B cells at varied stages of growth medicine 3601 buy 5mg kemadrin with amex. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma my medicine kemadrin 5mg for sale. Epigenetic processes play a major position in B-cell-specific gene silencing in classical Hodgkin lymphoma. Terms of Use � Privacy Policy � Notice � Accessibility illness supplies further evidence for its B-cell origin. Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Flow sorting and exome sequencing reveal the oncogenome of main Hodgkin and Reed-Sternberg cells. Interleukin thirteen is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. Functional expression of receptor activator of nuclear issue B in Hodgkin disease cell traces. Tumor-associated macrophages predict inferior outcomes in basic Hodgkin lymphoma: a correlative research from the E2496 Intergroup trial. Outcome of patients with early-stage infradiaphragmatic Hodgkin lymphoma: a comprehensive analysis from the German Hodgkin Study Group. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive sufferers with Hodgkin lymphoma. Molecular diagnosis of main mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse giant B cell lymphoma related to Hodgkin lymphoma. Terms of Use � Privacy Policy � Notice � Accessibility trials in Hodgkin lymphoma. The predictive position of interim positron emission tomography for Hodgkin lymphoma therapy consequence is confirmed utilizing the interpretation standards of the Deauville five-point scale. Prognostic worth of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Gene expression-based model utilizing formalin-fixed paraffin-embedded biopsies predicts total survival in advanced-stage classical Hodgkin lymphoma. Modern radiation remedy for Hodgkin lymphoma: subject and dose tips from the international �2021 McGraw Hill. The influence of breakthrough clinical trials on survival in inhabitants based mostly tumor registries. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and 187. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in sufferers with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Nivolumab plus doxorubicin, vinblastine and dacarbazine for newly recognized advanced-staged classical Hodgkin lymphoma: CheckMate 205 cohort D 2-year follow-up. High-dose chemotherapy followed by autologous stem cell transplantation for sufferers with relapsed/refractory Hodgkin lymphoma. The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin illness: evaluation by intent to deal with and improvement of a prognostic mannequin. Pretransplantation useful imaging predicts consequence following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Five-year survival and sturdiness results of brentuximab vedotin in patients with relapsed or refractory Hodgkin �2021 McGraw Hill. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Five-year survival and sturdiness results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin plus bendamustine: a extremely lively first salvage routine for relapsed or refractory Hodgkin lymphoma. Interim outcomes of brentuximab vedotin together with nivolumab in sufferers with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin and nivolumab for relapsed or refractory traditional Hodgkin lymphoma: long-term follow-up results from the single-arm part half examine. A part 2 multicenter research of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Phase 2 research of everolimus for relapsed or refractory classical Hodgkin lymphoma. Gemcitabine, fludarabine, and melphalan for reduced-intensity conditioning and allogeneic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Haploidentical transplants with post-transplant cyclophosphamide for relapsed or refractory Hodgkin lymphoma: the role of comorbidity index and pretransplant positron emission tomography. Greater consideration should be paid to creating therapies for elderly sufferers with Hodgkin lymphoma -a population-based examine from Sweden. The efficacy and tolerability of Adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma sufferers: a complete analysis from the North American intergroup trial E2496. The efficacy and tolerability of Adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Countway Medical Library Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Independent prognostic effect of co-morbidity in lymphoma sufferers: outcomes of the population-based Eindhoven Cancer Registry. Impact of tumor Epstein-Barr virus standing on presenting options and outcome in age-defined subgroups of patients with basic Hodgkin lymphoma: a population-based study. Phase 2 examine of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma sufferers aged 60 years and older. Phase 2 study of frontline brentuximab vedotin plus nivolumab in patients with Hodgkin lymphoma aged 60 years. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for aged sufferers with poor-prognosis lymphoma. How I deal with classical Hodgkin lymphoma in patients contaminated with human immunodeficiency virus. Lymphoma occurring during being pregnant: antenatal therapy, issues, and maternal survival in a multicenter analysis. Obstetric and maternal outcomes in sufferers recognized with Hodgkin lymphoma throughout being pregnant: a Page 54 / 61, Michael A. Terms of Use � Privacy Policy � Notice � Accessibility multicentre, retrospective, cohort examine. Impact of radiotherapy on fertility, being pregnant, and neonatal outcomes in female most cancers sufferers. Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience. Obstetric and maternal outcomes in patients identified with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort research.

Sheehan syndrome

Generic 5mg kemadrin amex

Circulating proteasome levels are an independent prognostic issue for survival in multiple myeloma medications contraindicated in pregnancy buy genuine kemadrin. Presenting features and prognosis in seventy two patients with multiple myeloma who were youthful than 40 years 3 medications that cannot be crushed discount kemadrin 5mg without a prescription. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Le Baccon P, Bastard C, Brigaudeau C, et al; Groupe Fran�ais de Cytog�n�tique H�matologique. Novel evidence of a job for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and a number of myeloma. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Genomic instability in a number of myeloma: evidence for leaping segmental duplications of chromosome arm 1q. Safety of extended remedy with bortezomib in relapsed or refractory a quantity of myeloma. Benefit of complete response in a quantity of myeloma limited to high-risk subgroup recognized by gene expression profiling. Ectopic expression of fibroblast development issue receptor three promotes myeloma cell proliferation and prevents apoptosis. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Identification of genes regulated by dexamethasone in a quantity of myeloma cells using oligonucleotide arrays. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory a quantity of myeloma variants. Prognostic factors and response to fludarabine remedy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. The natural historical past of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis. Detection of malignant bone marrow involvement with dynamic contrast-enhanced magnetic resonance imaging. Non-invasive demonstration of cardiac involvement in acquired forms of systemic amyloidosis. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in sufferers with asymptomatic multiple myeloma. Challenges and alternatives of novel imaging techniques in monoclonal plasma cell disorders: imaging "early myeloma". Monoclonal gammopathy of undetermined significance and smoldering a quantity of myeloma: biological insights and early treatment strategies. Randomized trial of lenalidomide versus observation in smoldering a quantity of myeloma. A section 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Persistent total survival benefit and no elevated risk of second malignancies with bortezomib�2021 McGraw Hill. Terms of Use � Privacy Policy � Notice � Accessibility melphalan-prednisone versus melphalan-prednisone in sufferers with previously untreated a number of myeloma. Persistent overall survival profit and no elevated risk of second malignancies with bortezomibmelphalan-prednisone versus melphalan-prednisone in sufferers with beforehand untreated a quantity of myeloma. Improvement in general survival with carfilzomib, lenalidomide, and dexamethasone in sufferers with relapsed or refractory a number of myeloma. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Terms of Use � Privacy Policy � Notice � Accessibility Page 89 / 89 Countway Medical Library Access Provided by: Williams Hematology, 10e Chapter 107: Immunoglobulin Light Chain Amyloidosis Morie A. When a affected person is seen with a compatible syndrome, the affected person ought to have immunofixation of serum, immunofixation of urine, and and immunoglobulin free gentle chains. If any of the above exams are positive, further investigation for amyloidosis should be undertaken. With those two checks, 83% of sufferers could have a optimistic result when the sample is stained with Congo red and seen with green birefringence. All sufferers with biopsy-proven amyloidosis ought to have the deposits analyzed by laser capture microdissection mass spectroscopy to definitively classify the precise protein subunit composing the amyloid. Fit patients would be expected to have low morbidity with this modality of remedy. Amyloidosis is a heterogeneous group of illnesses characterised by tissue infiltration with misfolded protein. Divry and Florkin first used Congo red to detect amyloid in the brain of patients with Alzheimer disease. Amyloid deposits are all the time extracellular and, underneath the sunshine microscope, seem amorphous. Terms of Use � Privacy Policy � Notice � Accessibility and must be replaced by immunoglobulin light-chain amyloidosis, reflecting the truth that it represents a systemic plasma cell neoplasm. For more than one hundred years, amyloid has Countway Medical Library Access Provided by: been outlined by its staining properties. The time period "major amyloid" is obsolete and ought to be replaced by immunoglobulin light-chain amyloidosis, reflecting the fact that it represents a systemic plasma cell neoplasm. Practicing hematologists and oncologists are much less likely to see patients with forms of amyloidosis aside from immunoglobulin light-chain amyloidosis. However, referrals are widespread without identification of the subunit protein so the hematologist must be aware of all varieties earlier than contemplating remedy. Buadi represents roughly 52% of all amyloid patients seen on the Mayo Clinic, and immunoglobulin heavy-chain amyloidosis represents <1% of all �2021 McGraw Hill. A normal immunoglobulin gentle chain has a molecular weight of roughly 25 kD. The immunoglobulin mild chains present in amyloid deposits often range from eight kD�15 kD. The fragment measurement is necessary as a outcome of it usually displays the deletion of the fixed region of the immunoglobulin mild chain, making immunohistochemistry a poor technique to try to identify the fibril sort in paraffin-embedded tissues. A translocation t(11;14) is seen in half of amyloidosis patients and seems to confer bortezomib resistance and an inferior end result. Circulating plasma cells detected by move cytometry are uncommonly seen in contrast with their excessive frequency in sufferers with myeloma, but their presence additionally predicts inferior outcomes. Physical findings, when current, can be highly specific but are only found in the minority of patients.

References

  • Neville H, Ritchey ML, Shamberger RC, et al: The occurrence of Wilms tumor in horseshoe kidneys, J Pediatr Surg 37:1134n1137, 2002.
  • Iinuma T, Hirota Y, Ishio K. Orbital wall fractures: conventional views and CT. Rhinology. 1994;32:81-83.
  • Friedlander DA, Ludwig WW, Jayman JR, et al: The effect of prior endoscopic correction of vesicoureteral reflux on open ureteral reimplantation: surgical outcomes and costs, J Pediatr Urol 14(3):268.e1n268.e5, 2018.
  • Motrich RD, Maccioni M, Riera CM, et al: Autoimmune prostatitis: state of the art, Scand J Immunol 66:217n227, 2007.
  • Tasali E, Leproult R, Ehrmann DA, et al: Slow-wave sleep and the risk of type 2 diabetes in humans, Proc Natl Acad Sci USA 105:1044n1049, 2008.
  • 08.038. Shakirova Y, Hedlund P, Sward K: Impaired nerve-mediated relaxation of penile tissue from caveolin-1 deficient mice, Eur J Pharmacol 602(2n3):399n 405, 2009.
  • Johnson TM 2nd, Jones K, Williford WO, et al. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 2003;170:145-8.
  • Danila DC, Fleisher M, Scher HI: Circulating tumor cells as biomarkers in prostate cancer, Clin Cancer Res 17:3903n3912, 2011.